Palla Pharma Limited provided revenue guidance for the fiscal year 2019. Fiscal year 2019 revenue is expected to be $60+ million driven by continued API, external NRM and opiate based FDF sales.

API production capacity will increase a further 50% to over 1,500kg/week by fourth quarter of 2019 with a circa $100,000 capital investment required. This will bring API production capacity to 70t per annum.